The present analysis assessed the short-term cost-effectiveness of oral semaglutide versus empagliflozin 25 mg, sitagliptin 100 mg and liraglutide 1.8 mg for treatment of patients with type 2 diabetes, in terms of the cost per patient achieving treatment targets in the US setting
Moreover, ipamorelins specificity for GH release, akin to growth hormone-releasing hormone (GHRH), makes it a promising candidate for clinical development
Clinical data and our experience suggest that Tirzepatide, as a dual-agonist, can lead to slightly faster and greater overall weight loss for some individuals
These products are not intended for human consumption, veterinary use, therapeutic use, diagnostic use, or resale as consumer goods
IQVIA EMEA Thought Leadership analysis Once the existing supply-demand gap has been resolved, we expect the obesity market will begin to exhibit more orthodox dynamics, driven by choice and competitive strategies seeking differentiation that is anchored on addressing specific unmet needs in discrete patient sub-populations
Mood: Find your balance, find your clarity
